NervGen Pharma Corp. (NGEN) vs Veraxa Biotech AG (VRXA)

NervGen Pharma Corp. and Veraxa Biotech AG are both Biotechnology companies. NervGen Pharma Corp. and Veraxa Biotech AG are of similar size ($143.1M and $140.4M).

Valuation

Metric NGEN VRXA Biotechnology median
P/E n/m — 10.60
P/S n/m — 9.40
P/B 3.63 — 2.13
Price to free cash flow n/m — 25.18
EV/EBITDA n/m — 0.66
EV/Sales n/m — 9.02
Earnings yield (17.89%) — (32.88%)
Free cash flow yield (14.96%) — (23.13%)

Profitability

Metric NGEN VRXA Biotechnology median
Gross margin — — 68.51%
Operating margin 0.00% — 0.00%
Net margin 0.00% — 0.00%
Free cash flow margin 0.00% — 0.00%
Return on equity (94.85%) — (51.96%)
Return on assets (40.66%) — (46.06%)
Return on invested capital 0.00% — 0.00%

Growth

Metric NGEN VRXA Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (68.14%) — 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric NGEN VRXA Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 2.07 — 4.97
Net debt to EBITDA 0.95 — 1.01

Dividend

Metric NGEN VRXA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NGEN VRXA Biotechnology median
Market cap 143.13m 140.35m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack